ArticleApplied biochemistry and biotechnology2026
Dynamic Intracellular Trafficking of the Low Molecular Weight Protamine in Breast Cancer Cells.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Low molecular weight protamines (LMWPs) are polycationic peptide fragments that possess a high capability of penetrating cells with low toxicity. These peptides have been utilized to produce innovative pharmaceutical formulations for gene delivery systems and nanopharmaceutical particles. Despite the potential impact of LMWPs for therapeutic applications their subcellular trafficking pathways, particularly the translocation to the nuclear/nucleolar region, is not completely understood. Targeting delivery of drugs to these compartments could be utilized to treat diseases like breast cancer to increase drug efficiency, reduce side toxicity and overcome drug resistance mechanisms. In this study, the dynamic trafficking of the LMWP fragment (Pep2) to the nuclear/nucleolar compartment has been analyzed in breast cancer cell lines using laser scanning confocal microscopy and live-cell imaging techniques. Also, the present study determines a key part of the LMWP trafficking: a potential nuclear/nucleolar localization sequence (NLS/NoLS) that could be associated with the peptide. Indeed, we have identified the specific sequence (RRRRRGGRRRR) as a potential NLS/NoLS that could be required by the LMWP fragment (Pep2) for its trafficking and accumulation in the nuclear/nucleolar compartments. The functionality of the sequence has been validated using mutagenesis experiments combined with microscopic analysis in cells. The findings of this study could be utilized to improve the efficiency of various LMWP-containing biopharmaceutical formulations, probably through modulation of their subcellular localization.
Indexed as
Identifiers
41801553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.